Spyre Therapeutics (SYRE) Net Margin (2015 - 2023)
Spyre Therapeutics (SYRE) posted Net Margin of 31552.47% for Q2 2023, down 239.13% on a QoQ basis from 9304.04% in Q1 2023, and down 2798079.0% year-over-year from N/an in Q2 2022.
Spyre Therapeutics (SYRE) Net Margin (2015 - 2023) Analysis & Trends
Spyre Therapeutics' Net Margin history runs 7 years deep, the most recent figure standing at 31552.47% for Q2 2023.
- Quarterly Net Margin fell 2798079.0% year-over-year to 31552.47% in Q2 2023, while the trailing twelve-month figure through Mar 2024 was 52939.68% (down 4626148.0% YoY) and the FY2023 annual result came in at 38238.15%, down 3463939.0% from the prior year.
- Net Margin was 31552.47% for Q2 2023 at Spyre Therapeutics, down from 9304.04% in the prior quarter.
- Across five years, Net Margin topped out at 49.87% in Q2 2021 and bottomed at 31552.47% in Q2 2023.
- A 3-year average of 7631.71% and a median of 3571.68% in 2022 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin slumped 352181 bps — and 2023, when it tumbled 2798079 bps.
- Spyre Therapeutics' Net Margin stood at 561.09% in 2021, then sank by 1897 bps to 11203.57% in 2022, then slumped by 182 bps to 31552.47% in 2023.
- Business Quant data shows SYRE's Net Margin at 31552.47% in Q2 2023, 9304.04% in Q1 2023, and 11203.57% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -31,552.47% |
| Mar 31, 2023 | -9,304.04% |
| Dec 31, 2022 | -11,203.57% |
| Sep 30, 2022 | -10,479.31% |
| Jun 30, 2022 | -3,571.68% |
| Mar 31, 2022 | -1,794.13% |
| Dec 31, 2021 | -561.09% |
| Sep 30, 2021 | -169.23% |
| Jun 30, 2021 | -49.87% |
| Jun 30, 2018 | -407.57% |
| Mar 31, 2018 | -545.76% |
| Dec 31, 2017 | -604.11% |
| Sep 30, 2017 | -623.47% |
| Jun 30, 2017 | -447.60% |
| Mar 31, 2017 | -664.66% |
| Dec 31, 2016 | -439.70% |
| Sep 30, 2016 | -542.91% |
| Jun 30, 2016 | -395.48% |
| Mar 31, 2016 | -529.34% |
| Dec 31, 2015 | -251.55% |